Imaging outcome measures of neuroprotection and repair in MS

In the article "Imaging outcome measures of neuroprotection and repair in MS: A consensus statement from NAIMS" by Oh et al.,¹ first published online February 20, 2019, and in print March 12, 2019, Dr. Robert Zivadinov should have been listed as an author, appearing between Yunyan Zhang and Nancy Sicotte. The authors regret the error.

Dr. Zivadinov’s disclosures should have been included as follows: Dr. Zivadinov has received personal compensation from Genzyme and Novartis for serving on scientific advisory boards; received speaker honoraria from EMD Serono, Inc., Novartis, Sanofi-Genzyme, and Celgene; received personal compensation from EMD Serono, Inc., Novartis, Sanofi-Genzyme for consulting fees; received personal compensation from EMD Serono, Inc., Novartis, and Sanofi-Genzyme for serving on speakers’ bureaus; and financial support for research activities from EMD Serono, Inc., Novartis, Sanofi-Genzyme, Mapi Pharma, Celgene, and Protembis.

Dr. Zivadinov’s full degrees and affiliation are as follows:

Robert Zivadinov, MD, PhD

Professor of Neurology

Director, Buffalo Neuroimaging Analysis Center, Department of Neurology

Director, Center for Biomedical Imaging at the Clinical Translational Science Institute

Jacobs School of Medicine & Biomedical Sciences

University at Buffalo, State University of New York

Finally, Dr. ZIvadinov’s contributions to the paper should have been: Dr. Zivadinov contributed to the acquisition of data, analysis and interpretation, and critical revision of the manuscript for important intellectual content.